Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2026 08:00 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026

Advancing FDA-Cleared Phase IIa Parkinson’s Program Targeting Neuroinflammation Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia™ JUPITER, FL, March 02, 2026 (GLOBE...
December 26, 2023 07:59 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

60 Degrees Pharma has received IRB approval for a Phase IIA study evaluating tafenoquine's efficacy in treating hospitalized babesiosis patients, while the